|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,501 GBX | +0.20% |
|
-0.60% | +3.50% |
Jan 24 (Reuters) - ELEGEN:
* ELEGEN AND GSK SIGN COLLABORATION AND LICENSING AGREEMENT TO FURTHER DEVELOP ELEGEN’S CELL-FREE DNA PRODUCTION TECHNOLOGY
* ELEGEN - TERMS OF AGREEMENT INCLUDE UPFRONT FEES AND PURCHASE COMMITMENTS OF ELEGEN'S ENFINIA DNA
* ELEGEN - AGREEMENT PROVIDES ELEGEN UP TO $35 MILLION IN NEAR-TERM FINANCIAL AND DEVELOPMENT SUPPORT Further company coverage:
| 1st Jan change | Capi. | |
|---|---|---|
| +3.50% | 79.32B | |
| +62.03% | 856B | |
| +38.95% | 631B | |
| -4.03% | 359B | |
| +15.87% | 325B | |
| +8.72% | 297B | |
| +5.89% | 234B | |
| +16.53% | 226B | |
| +15.78% | 177B | |
| +2.01% | 165B |
GSK PLC 
